
Ehave, Inc. (OTC:EHVVF), a healthcare company developing digital solutions in the medical cannabis and mental health sectors, reported that its wholly-owned subsidiary, KetaDASH, is offering in-home ketamine therapy to patients suffering from treatment-resistant mental health issues. As reported by Green Market Report, the treatment will be available first in the San Francisco Bay Area and Greater Sacramento Area.
“I have over-seen over 600 successful ketamine treatments and have been amazed by the positive results,” said Jeffrey D. Kamlet, MD, chief medical officer of Ehave. “We are pleased to begin our U.S. rollout in Sacramento and San Francisco, with plans to scale our business in other cities over the coming months.”